Trial Profile
DETECT III - A Multicenter, Randomized, Phase III Study to Compare Standard Therapy Alone Versus Standard Therapy Plus Lapatinib in Patients With Initially HER2-negative Metastatic Breast Cancer and HER2-positive Circulating Tumor Cells
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 15 Jan 2024
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Lapatinib (Primary) ; Anastrozole; Capecitabine; Docetaxel; Doxorubicin; Exemestane; Letrozole; Paclitaxel; Vinorelbine
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms DETECT-III
- 09 Jan 2024 According to Menarini Silicon Biosystems media release, data from the study were presented at Journal of Clinical Chemistry.
- 09 Jan 2024 Results presented in the Menarini Silicon Media Release.
- 04 Jan 2024 Primary endpoint (CTC clearance rate) has been met.